Title: Bangladesh Pharma Industry
1 Bangladesh Pharma Industry
Dr. Brian W Tempest www.briantempest.com UNCTAD
Investment Policy Review of Bangladesh United
Nations Palais des Nations Geneva, Switzerland 29
April 2014
2Dr Brian Tempest advises Companies, Banks, High
Net Worth Individuals and Investment Funds on
their Strategy in the Emerging World based on
his wide experience in China, Japan, South East
Asia and India where he has lived for the last
decade. Brian has worked for Ranbaxy Laboratories
since 1995 holding the position of Managing
Director and Chief Executive Officer until 2005.
He was then Chief Mentor and Non Executive
Director until 2008 when he retired. He is one
of the few westerners to have led a Sensex Nifty
50 Indian blue Chip MNC and as a result has a
valuable insight into India. Brian has also
worked for Glaxo as Regional Director Far East
and Regional Director Middle East Africa from
1985 to 1992. Brian has worked in the
Pharmaceutical Industry for the last 41 years and
has managed Healthcare businesses in North
America, South America, Europe, Africa, Middle
East, Australasia, China, Japan and India. He has
also led many sessions at Investor Meetings held
around the world. He is now Independent Chairman
of Religare Capital Markets PLC , a Non Executive
Director of Fortis Healthcare the leading Asian
Healthcare Company, a Non Executive Director of
SRL the largest Indian Diagnostic Company and a
Non Executive Director of Glenmark
Pharmaceuticals. He is a member of the SCRIP
Global awards panel and is on the Editorial
Board of the Journal of Generic Medicines. Brian
speaks at global conferences and more information
on these presentations can be found on his
website www.briantempest.com. Brian has a PhD in
Polymer Chemistry from Lancaster University in
1971 and in 2009 he became Chairman of the
Advisory Board for the Lancaster University
Management School, UK. He is a Fellow of the
Royal Society of Medicine and a Fellow of the
Royal Society of Chemistry and is a Chartered
Chemist. He is now Chairman and Senior Partner
of Hale Tempest Co Ltd
3Global Pharma Salessource Evaluate April 2014
4Bangladesh vs India Universal Healthcare source
ET 2 Aug 2013
5Bangladesh Injectables Inhalerssource
Beximco 2014
6Bangladesh Pharmasource Beximco 2014
7Bangladesh Pharma - Beximcosource Beximco 2014
8Bangladesh Pharma - Beximcosource Beximco 2014
9Bangladesh Pharma - Beximcosource Beximco 2014
10Recommended Strategies to encourage further
investment in Bangladesh Pharma
- Bangladesh is nearly self sufficient in Pharma
production - Current Pharma Exports of around 100m per year
can easily rise to b with support from the
Bangladesh Government and other Governments - The following Government strategies are
recommended
11Recommended Strategies to encourage further
investment in Bangladesh Pharma
- High quality training and technological support
from developed countries as per Doha
Declaration to enhance Pharma capabilities in RD - Preferential tender prices from other LDCs for
their complex Pharma products which are not made
locally such as injectables and inhalers - In Bangladesh do not effect price cuts on the
home market as Bangladesh companies need to make
money at home in order to expand overseas. This
is one of the reasons for the great success of
Indian Generic Industry and the limited success
of the Chinese Generic Industry
12Pharma Manufacturingsource ABPI
13Recommended Strategies to encourage further
investment in Bangladesh Pharma
- Encourage a API raw material industry which has
hardly any presence in Bangladesh with an API
park could be set up with acceptable
environmental controls - Establish 2/3 SEZs with favorable tax treatments
India has more than a dozen of these and they
are actively used - Better collaboration between academia and the
pharma Industry to enhance RD - Government road shows around the world
highlighting the potential of the Bangladesh
Pharma Industry like what happened in Brazil a
decade ago
14 brian.tempest_at_clara.co.uk www.briantempest.com